Trial Profile

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigimadlin (Primary) ; Ezabenlimab (Primary)
Indications Biliary cancer; Colorectal cancer; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
Focus Proof of concept; Therapeutic Use
Acronyms EMPIRE

Most Recent Events

02 Sep 2025 Actual primary completion date changed to 1 Jul 2024.
02 Sep 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
18 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com